Previous close | 67.08 |
Open | 66.59 |
Bid | 65.26 x 600 |
Ask | 65.31 x 300 |
Day's range | 65.27 - 67.90 |
52-week range | 65.27 - 87.87 |
Volume | |
Avg. volume | 7,193,293 |
Market cap | 81.421B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 14.51 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (4.59%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.